Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global home infusion therapy market was valued at US$ 45.77 billion in 2021 and is expected to register a revenue CAGR of 5.95% to reach US$ 77.1 billion by 2030. 

Home Infusion Therapy Market Fundamentals

Infusion therapy involves medication administration through a needle or catheter. Infusion therapy is administered when a patient's illness is sufficiently severe that oral treatments are ineffective. Infusion treatment often refers to administering a medicine intravenously. However, infusion therapy is also applicable when pharmaceuticals can be administered through other non-oral channels, such as intramuscular injections and epidural routes. Parenteral nutrition, chemotherapy, antibiotics, antifungal, antiviral, hydration, and pain management are conventional prescription treatments routinely administered through infusion. Patients are also offered infusion therapy to treat a wide range of chronic and sometimes uncommon conditions for which specialty infusion drugs are beneficial. Common infusion items include blood factors, corticosteroids, erythropoietin, infliximab, inotropic cardiac medicines, growth hormones, immunoglobulin, and natalizumab. 

Intravenous or subcutaneous administration of drugs to an individual in a home care setting is called home infusion therapy. Diseases such as infections, gastrointestinal ailments and disorders, dehydration, congestive heart failure, multiple sclerosis, rheumatoid arthritis, hemophilia, immunological deficiencies, neurological problems, and other conditions frequently necessitate home infusion therapy. Home infusion is a safe and effective alternative to inpatient care for several acute and chronic illnesses. Home infusion is a more cost-effective option for patients with chronic conditions than a long hospital stay or nursing home placement. Home infusion treatment offers speedier recovery, a better experience, fewer problems, and cost-effectiveness, dramatically improving the quality of life of a patient.

[796987]

Home Infusion Therapy Market Dynamics

The increased prevalence of chronic diseases, such as dementia, Parkinson's disease, chronic obstructive pulmonary disease, arthritis, heart disease, and stroke, is driving the global home infusion therapy market. Diabetes has become more prevalent in recent decades, and is expected to fuel revenue growth in the home infusion treatment industry since it requires insulin, nutrients, antibiotics, and other regulated fluids. Diabetes prevalence has climbed by nearly 60% in the United Kingdom, according to the National Health Service (NHS). Furthermore, as medical practices and procedures continue to improve, there is a global growth in demand for home infusion treatment equipment. The increasing number of home infusion providers is likely to boost the overall uptake of home infusion therapy, driving the industry forward. The application of artificial intelligence and machine learning in home-based treatment creates substantial potential for revenue growth in the home infusion therapy industry.

However, safety issues and failure risks associated with home infusion devices, as well as the presence of complex reimbursement frameworks and payment in emerging markets, are projected to impede the overall revenue growth of the home infusion therapy market.

Home Infusion Therapy Market Ecosystem

The global home infusion therapy market has been analyzed from three perspectives: application, product, and region.

Home Infusion Therapy Market by Application

[548766]

Based on the application, the global home infusion therapy market is segmented into total parenteral nutrition​, anti-infective therapy, endocrinology, enteral nutrition hydration therapy, chemotherapy, specialty pharmaceuticals, and other applications.

The anti-infective therapy segment dominated the market in 2021 due to increase in the number of operations performed during the administration of pharmaceuticals, such as antibiotics and antifungals. With the increasing incidence of infectious disorders, anti-infective treatment is one of the most prescribed home infusion therapies. For instance, an estimated 10.6 million individuals worldwide fell ill with tuberculosis in 2021. About 6 million men, 3.4 million women, and 1.2 million children make up the population. In addition, tuberculosis is the 13th largest cause of mortality and the second leading infectious killer after COVID-19. Furthermore, increased awareness campaigns from different government organizations, as well as a rise in expenditures in research and development to improve the existing therapies for infectious illnesses, are likely to boost the overall anti-infective therapy market revenue growth during the forecast period.

Home Infusion Therapy Market by Product

Based on the product, the global home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needless connectors​.

The infusion pumps segment dominated the market with the highest revenue share in 2021, attributed to an increased usage of delivery fluids, such as nutrition and pharmaceuticals. Infusion pumps are used to provide nutrients or pharmaceuticals, such as antibiotics, chemotherapeutic treatments, hormones such as insulin, and analgesics. Infusion system attachments provide several benefits, including administering fluids in metered quantities at precisely scheduled intervals. Ambulatory infusion pumps, elastomeric pumps, syringe pumps, insulin pumps, patient-controlled analgesics (PCA), and volumetric pumps are among the several types of infusion pumps available. Modernized infusion pumps have alarm systems to reduce the possibility of undesirable medication interactions or when the pump settings are set arbitrarily. These factors are expected to bolster the overall infusion pump segment.

Home Infusion Therapy Market by Region

Based on the region, the global Home Infusion Therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

Due to the availability of great healthcare facilities, faster acceptance of modern technologies, and an increasing elderly population, North America dominated the global home infusion therapy market in 2021. Patients benefit from human infusion treatment in a variety of ways. Among the advantages are cost-effectiveness, better results, convenience, and improved safety standards. Home infusion therapy is less expensive than hospital treatment since it avoids hospital stays, which saves the patient money. Home infusion treatment also helps the patient retain a better safety level because hospital-acquired illnesses are less likely to occur at home. This increases the demand for home treatment, fueling the growth of the home infusion therapy market in the United States. In addition, the growing number of home infusion treatment providers, and collaborations between small and large suppliers, are projected to boost revenue growth in the North America home infusion therapy market. For instance, in December 2022, WellSky, a premier health and community care technology business, established a collaboration with Option Care Health Inc., the nation's biggest independent provider of home and alternate site infusion services. With this collaboration, both companies were expected to play a vital role in developing the technology that drives infusion and specialty pharmacy operations in the quest for better results at reduced costs.

Home Infusion Therapy Market Competitive Landscape

The prominent players operating in the home infusion therapy market are:

• Becton, Dickinson, and Company
• Coram LLC.
• Option Care Health
• Baxter International Inc.
• KabaFusion
• PromptCare
• Fresenius Kabi AG
• Infusystem
• B. Braun SE
• Smiths Medical
• ICU Medical, Inc.
• JMS Co. Ltd.
• Diplomat Pharmacy, Inc.
• Eli Lily and Company

Home Infusion Therapy Market Strategic Developments

• In January 2023, Bexson Biomedical, Inc., a biopharmaceutical company focused on the small molecule injectable market and enabling home health solutions, announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) for Sevalent, its patented formulation technique. Sevalent is based on the company's main treatment, which uses ketamine to control postoperative pain. The patent might broaden the technology's application to include a broader spectrum of other small molecules, allowing intravenous (IV)-only medicines to be supplied subcutaneously in a regulated way for use at home.
• In November 2022, Medtronic plc announced the U.S. launch of the Medtronic Extended infusion set, the first and only infusion set approved for up to 7-day use. The Medtronic Extended infusion set aims to bring convenience to diabetes patients by providing them with longer and more comfortable wear. To double the wear duration of an infusion set, the Medtronic Extended infusion set employs innovative materials that assist in limiting insulin preservative loss while maintaining insulin flow and stability.
• In September 2022, KabaFusion, a major home infusion therapy supplier, announced the openings of infusion care pharmacies in sites purchased from Coram Infusion Services (Coram). KabaFusion's purchase expanded the company's capacity to serve a growing number of patients across the country. It reinforced its commitment to providing high-quality patient care across a wide spectrum of home infusion therapies. Furthermore, this purchase approximately doubled KabaFusion's home infusion segment presence. 

Frequently Asked Questions About This Report